BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 17253475)

  • 1. Phosphodiesterase inhibitors for erectile dysfunction in patients with diabetes mellitus.
    Vardi M; Nini A
    Cochrane Database Syst Rev; 2007 Jan; 2007(1):CD002187. PubMed ID: 17253475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [From the Cochrane Library: Phosphodiesterase inhibitors are effective in treating erectile dysfunction in diabetic men].
    Hamerlynck JV; Middeldorp S; Hooft L
    Ned Tijdschr Geneeskd; 2007 Sep; 151(38):2101-4. PubMed ID: 17948826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease.
    Conti CR; Pepine CJ; Sweeney M
    Am J Cardiol; 1999 Mar; 83(5A):29C-34C. PubMed ID: 10078540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vardenafil (Levitra) for erectile dysfunction: a systematic review and meta-analysis of clinical trial reports.
    Markou S; Perimenis P; Gyftopoulos K; Athanasopoulos A; Barbalias G
    Int J Impot Res; 2004 Dec; 16(6):470-8. PubMed ID: 15229625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction.
    Briganti A; Salonia A; Deho' F; Zanni G; Barbieri L; Rigatti P; Montorsi F
    World J Urol; 2005 Dec; 23(6):374-84. PubMed ID: 16273417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of tadalafil in men with erectile dysfunction naïve to phosphodiesterase 5 inhibitor therapy compared with prior responders to sildenafil citrate.
    Broderick GA; Donatucci CF; Hatzichristou D; Torres LO; Valiquette L; Zhao Y; Loughney K; Sides GD; Ahuja S
    J Sex Med; 2006 Jul; 3(4):668-675. PubMed ID: 16839323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Visual loss with erectile dysfunction medications.
    Wooltorton E
    CMAJ; 2006 Aug; 175(4):355. PubMed ID: 16870715
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacologic update: treatment of erectile dysfunction in the elderly with phosphodiesterase type 5 inhibitors: cardiovascular implications.
    Agarwal P; Sander GE; Giles TD
    Am J Geriatr Cardiol; 2004; 13(6):332-5. PubMed ID: 15538074
    [No Abstract]   [Full Text] [Related]  

  • 9. Phosphodiesterase 5 inhibitors for erectile dysfunction.
    Setter SM; Iltz JL; Fincham JE; Campbell RK; Baker DE
    Ann Pharmacother; 2005; 39(7-8):1286-95. PubMed ID: 15941818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
    Montani D; Chaumais MC; Savale L; Natali D; Price LC; Jaïs X; Humbert M; Simonneau G; Sitbon O
    Adv Ther; 2009 Sep; 26(9):813-25. PubMed ID: 19768639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New phosphodiesterase type 5 inhibitors in the management of erectile dysfunction.
    Mason RG
    J R Soc Promot Health; 2003 Jun; 123(2):79-80. PubMed ID: 12852189
    [No Abstract]   [Full Text] [Related]  

  • 12. Phosphodiesterase 5 inhibitors in male sexual dysfunction.
    Kuthe A
    Curr Opin Urol; 2003 Sep; 13(5):405-10. PubMed ID: 12917517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus.
    Vickers MA; Satyanarayana R
    Int J Impot Res; 2002 Dec; 14(6):466-71. PubMed ID: 12494279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vardenafil: a review of its use in erectile dysfunction.
    Keating GM; Scott LJ
    Drugs; 2003; 63(23):2673-703. PubMed ID: 14636086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of tadalafil in a Western European population of men with erectile dysfunction.
    Eardley I; Gentile V; Austoni E; Hackett G; Lembo D; Wang C; Beardsworth A
    BJU Int; 2004 Oct; 94(6):871-7. PubMed ID: 15476525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphodiesterase-5 inhibitors: clinical market and basic science comparative studies.
    McCullough A
    Curr Urol Rep; 2004 Dec; 5(6):451-9. PubMed ID: 15541215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphodiesterase-5 inhibitors and their hemodynamic effects.
    Prisant LM
    Curr Hypertens Rep; 2006 Aug; 8(4):345-51. PubMed ID: 16884667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential effects of phosphodiesterase-5 inhibitors on hypoxic pulmonary vasoconstriction and pulmonary artery cytokine expression.
    Tsai BM; Turrentine MW; Sheridan BC; Wang M; Fiore AC; Brown JW; Meldrum DR
    Ann Thorac Surg; 2006 Jan; 81(1):272-8. PubMed ID: 16368379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction.
    Kloner RA
    Circulation; 2004 Nov; 110(19):3149-55. PubMed ID: 15533876
    [No Abstract]   [Full Text] [Related]  

  • 20. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil--review of the literature.
    Gresser U; Gleiter CH
    Eur J Med Res; 2002 Oct; 7(10):435-46. PubMed ID: 12435622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.